BLUE BELL, Pa.--(BUSINESS WIRE)--Aug. 11, 1997-- Phase One of Implementation Shows Department Reaps Productivity Increase of 400%; Image-Based Processing System To Completely Automate Sales, Employer Withholding and Income Tax Processes Unisys ...

LORAIN, Ohio--(BUSINESS WIRE)--Aug. 11, 1997--In today's cost-conscious times, law firms both large and small are continually faced with cost issues surrounding staff members who support a firm's base of attorneys. The question that often perplexes management...

Table 1 Glaucoma: Clinical Indications for Referral to an Ophthalmologist or Optometrist Purpose of referral Clinical indications Screening a high-risk Blacks older than 40 years patient Whites older than 65 years ...

ROCHESTER, N.Y.--(BUSINESS WIRE)--June 27, 1995--Bausch & Lomb (NYSE/BOL) announced today that its U.S. Pharmaceutical Division has received clearance to begin marketing Dipivefrin Hydrochloride Ophthalmic Solution USP, 0.1%, a generic equivalent to Propine(R)(a). D...

ROCHESTER, N.Y.--(BUSINESS WIRE)--Feb. 15, 1995--Bausch & Lomb (NYSE:BOL) announced today that its U.S. Pharmaceutical business has received clearance to begin marketing CROLOM(TM) cromolyn sodium sterile ophthalmic solution 4%. CROLOM(TM), indicated for the relief...

CLINICAL CHALLENGES ...

CLINICAL CHALLENGES ...

Glaucoma treatments generally focus on reducing intraocular pressure to a level your health care professional believes will not cause further damage to the optic nerve. This level is often called the "target pressure," and it differs from person to person, a...

Little more than 20 years ago, optometrists could barely diagnose glaucoma, let alone treat it. Today, optometrists in 44 states can treat, and more and more optometrists are taking advantage of this opportunity. ...

ROCHESTER, N.Y.--(BUSINESS WIRE)--June 27, 1995--Bausch & Lomb (NYSE/BOL) announced today that its U.S. Pharmaceutical Division has received clearance to begin marketing Dipivefrin dipivefrin /di·piv·e·frin/ (di-piv´ah-frin) an ester converted in the eye ...

ALAMEDA, Calif.--(BUSINESS WIRE)--July 20, 1995--InSite Vision Incorporated (NASDAQ:INSV INSV - Impatiens Necrotic Spot Virus) today announced positive results of a second Phase III clinical study using its sustained-release PilaSite(R) eyedrop formulation of pilocarp...

SAN FRANCISCO--(BUSINESS WIRE)--Jan. 11, 1995--Today at the Hambrecht & Quist Annual Life Sciences Conference in San Francisco, InSite Vision Inc. (NASDAQ:INSV INSV - Impatiens Necrotic Spot Virus) reported further progress in its glaucoma congenital glaucoma  th...

ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 2, 1994--InSite Vision Inc. (NASDAQ: INSV INSV - Impatiens Necrotic Spot Virus) has completed patient enrollment for the pivotal Phase III study of its BetaSite eyedrop formulation for the treatment of glaucoma congenital glauco...

ALAMEDA, Calif.--(BUSINESS WIRE)--March 30, 1995--InSite Vision Inc. (NASDAQ:INSV INSV - Impatiens Necrotic Spot Virus) today announced positive Phase III clinical study results using its BetaSite formulations of levobunolol levobunolol /le·vo·bu·no·lol/ (le?...

FLORHAM PARK, N.J.--(HealthWire)--March 1, 1996--Schein Pharmaceutical Inc. today announced that both Dipivefrin dipivefrin /di·piv·e·frin/ (di-piv´ah-frin) an ester converted in the eye to epinephrine, lowering intraocular pressure by decreasing the producti...

RICHMOND, British Columbia--(BUSINESS WIRE)--Aug. 11, 1997-- Helix 1. spiral (2). 2. the superior and posterior free margin of the pinna of the ear. a-helix , alpha helix the structural arrangement of parts of protein molecules in which a single polypeptide chain f...